The N-terminal domain of p53 is natively unfolded

Journal of Molecular Biology

Volumn 332, Issue 5, 2003, Pages 1131-1141

  Dawson, Roger ^a   Müller, Lin ^a   Dehner, Alexander ^a   Klein, Christian ^b   Kessler, Horst ^a   Buchner, Johannes ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

CD spectroscopy; IUP; Mdm2; NMR spectroscopy; p53

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; PROTEIN TERTIARY STRUCTURE; TERMINAL SEQUENCE;

EID: 0041384333     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2003.08.008     Document Type: Article

References (89)

1. Lane D.P. Cancer. p53, guardian of the genome. Nature. 358:1992;15-16.
2. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
3. Bargonetti J., Manfredi J.J., Chen X., Marshak D.R., Prives C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 7:1993;2565-2574.
4. Pavletich N.P., Chambers K.A., Pabo C.O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7:1993;2556-2564.
5. Wang Y., Reed M., Wang P., Stenger J.E., Mayr G., Anderson M.E., et al. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev. 7:1993;2575-2586.
6. Bell S., Hansen S., Buchner J. Refolding and structural characterization of the human p53 tumor suppressor protein. Biophys. Chem. 96:2002;243-257.
7. Fields S., Jang S.K. Presence of a potent transcription activating sequence in the p53 protein. Science. 249:1990;1046-1049.
8. Raycroft L., Wu H.Y., Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science. 249:1990;1049-1051.
9. Kern S.E., Kinzler K.W., Bruskin A., Jarosz D., Friedman P., Prives C., Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science. 252:1991;1708-1711.
10. Sturzbecher H.W., Brain R., Addison C., Rudge K., Remm M., Grimaldi M., et al. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene. 7:1992;1513-1523.
11. Iwabuchi K., Li B., Bartel P., Fields S. Use of the two-hybrid system to identify the domain of p53 involved in oligomerization. Oncogene. 8:1993;1693-1696.
12. Arrowsmith C.H., Morin P. New insights into p53 function from structural studies. Oncogene. 12:1996;1379-1385.
13. Arrowsmith C.H. Structure and function in the p53 family. Cell Death Differ. 6:1999;1169-1173.
14. Ahn J., Prives C. The C-terminus of p53: the more you learn the less you know. Nature Struct. Biol. 8:2001;730-732.
15. Rustandi R.R., Baldisseri D.M., Weber D.J. Structure of the negative regulatory domain of p53 bound to S100B(betabeta). Nature Struct. Biol. 7:2000;570-574.
16. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 265:1994;346-355.
17. Clore G.M., Ernst J., Clubb R., Omichinski J.G., Kennedy W.M., Sakaguchi K., et al. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nature Struct. Biol. 2:1995;321-333.
18. Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H., Appella E., Gronenborn A.M. Interhelical angles in the solution structure of the oligomerization domain of p53: correction. Science. 267:1995;1515-1516.
19. Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H. Solution structure of the tetrameric minimum transforming domain of p53. Nature Struct. Biol. 1:1994;877-890.
20. Wong K.B., DeDecker B.S., Freund S.M., Proctor M.R., Bycroft M., Fersht A.R. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc. Natl Acad. Sci. USA. 96:1999;8438-8442.
21. Klein C., Planker E., Diercks T., Kessler H., Kunkele K.P., Lang K., et al. NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA. J. Biol. Chem. 276:2001;49020-49027.
22. Butler J.S., Loh S.N. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. Biochemistry. 42:2003;2396-2403.
23. Zhao K., Chai X., Johnston K., Clements A., Marmorstein R. Crystal structure of the mouse p53 core DNA-binding domain at 2.7 Å resolution. J. Biol. Chem. 276:2001;12120-12127.
24. Davison T.S., Nie X., Ma W., Lin Y., Kay C., Benchimol S., Arrowsmith C.H. Structure and functionality of a designed p53 dimer. J. Mol. Biol. 307:2001;605-617.
25. Jeffrey P.D., Gorina S., Pavletich N.P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 267:1995;1498-1502.
26. Gorina S., Pavletich N.P. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science. 274:1996;1001-1005.
27. Mittl P.R., Chene P., Grutter M.G. Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template. Acta Crystallog. sect. D. 54:1998;86-89.
28. Botuyan M.V., Momand J., Chen Y. Solution conformation of an essential region of the p53 transactivation domain. Fold. Des. 2:1997;331-342.
29. Chang J., Kim D.H., Lee S.W., Choi K.Y., Sung Y.C. Transactivation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATA-binding protein. J. Biol. Chem. 270:1995;25014-25019.
30. Lee H., Mok K.H., Muhandiram R., Park K.H., Suk J.E., Kim D.H., et al. Local structural elements in the mostly unstructured transcriptional activation domain of human p53. J. Biol. Chem. 275:2000;29426-29432.
31. Soussi T., May P. Structural aspects of the p53 protein in relation to gene evolution: a second look. J. Mol. Biol. 260:1996;623-637.
32. Sakamuro D., Sabbatini P., White E., Prendergast G.C. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene. 15:1997;887-898.
33. Walker K.K., Levine A.J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl Acad. Sci. USA. 93:1996;15335-15340.
34. Venot C., Maratrat M., Dureuil C., Conseiller E., Bracco L., Debussche L. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 17:1998;4668-4679.
35. Lu H., Levine A.J. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc. Natl Acad. Sci. USA. 92:1995;5154-5158.
36. Thut C.J., Chen J.L., Klemm R., Tjian R. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science. 267:1995;100-104.
37. Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., Pavletich N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 274:1996;948-953.
38. Bottger A., Bottger V., Garcia-Echeverria C., Chene P., Hochkeppel H.K., Sampson W., et al. Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol. 269:1997;744-756.
39. Uesugi M., Verdine G.L. The alpha-helical FXXPhiPhi motif in p53: TAF interaction and discrimination by MDM2. Proc. Natl Acad. Sci. USA. 96:1999;14801-14806.
40. Picksley S.M., Lane D.P. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays. 15:1993;689-690.
41. Wu X., Bayle J.H., Olson D., Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1993;1126-1132.
42. Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nature Rev. Cancer. 3:2003;102-109.
43. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
44. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 387:1997;299-303.
45. Chen J., Marechal V., Levine A.J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol. 13:1993;4107-4114.
46. Picksley S.M., Vojtesek B., Sparks A., Lane D.P. Immunochemical analysis of the interaction of p53 with MDM2; - fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene. 9:1994;2523-2529.
47. Bottger V., Bottger A., Howard S.F., Picksley S.M., Chene P., Garcia-Echeverria C., et al. Identification of novel mdm2 binding peptides by phage display. Oncogene. 13:1996;2141-2147.
48. Lin J., Chen J., Elenbaas B., Levine A.J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8:1994;1235-1246.
49. Kane S.A., Fleener C.A., Zhang Y.S., Davis L.J., Musselman A.L., Huang P.S. Development of a binding assay for p53/HDM2 by using homogeneous time-resolved fluorescence. Anal. Biochem. 278:2000;29-38.
50. Bell S., Klein C., Muller L., Hansen S., Buchner J. p53 contains large unstructured regions in its native state. J. Mol. Biol. 322:2002;917-927.
51. Uversky V.N., Fink A.L. Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle. FEBS Letters. 522:2002;9-13.
52. de la Torre J.G., Huertas M.L.C.B. HYDRONMR: prediction of NMR relaxation of globular proteins from atomic-level structures and hydrodynamic calculations. J. Magn. Reson. 147:2000;138-146.
53. Brünger A.T. X-PLOR Version 3.1. A System for X-ray Crystallography and NMR. 1992;Yale University Press, New Haven, London.
54. Stejskal E.O., Tanner J.E. Spin diffusion measurements - spin echoes in presence of a time-dependent field gradient. J. Chem. Phys. 42:1965;288.
55. Schon O., Friedler A., Bycroft M., Freund S.M., Fersht A.R. Molecular mechanism of the interaction between MDM2 and p53. J. Mol. Biol. 323:2002;491-501.
56. Blommers M.J.J., Fendrich G., Garcia-Echeverria C., Chene P. On the interaction between p53 and MDM2: transfer NOE study of a p53-derived peptide ligated to MDM2. J. Am. Chem. Soc. 119:1997;3425-3426.
57. Lai Z., Auger K.R., Manubay C.M., Copeland R.A. Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length. Arch. Biochem. Biophys. 381:2000;278-284.
58. Knight S.M., Umezawa N., Lee H.S., Gellman S.H., Kay B.K. A fluorescence polarization assay for the identification of inhibitors of the p53-DM2 protein-protein interaction. Anal. Biochem. 300:2002;230-236.
59. Sakaguchi K., Saito S., Higashimoto Y., Roy S., Anderson C.W., Appella E. Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. J. Biol. Chem. 275:2000;9278-9283.
60. Lai Z., Auger K.R., Manubay C.M., Copeland R.A. Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length. Arch. Biochem. Biophys. 381:2000;278-284.
61. Shimizu H., Burch L.R., Smith A.J., Dornan D., Wallace M., Ball K.L., Hupp T.R. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J. Biol. Chem. 277:2002;28446-28458.
62. Tompa P. Intrinsically unstructured proteins. Trends Biochem. Sci. 27:2002;527-533.
63. Dunker A.K., Lawson J.D., Brown C.J., Williams R.M., Romero P., Oh J.S., et al. Intrinsically disordered protein. J. Mol. Graph. Model. 19:2001;26-59.
64. Williams R.M., Obradovi Z., Mathura V., Braun W., Garner E.C., Young J., et al. The protein non-folding problem: amino acid determinants of intrinsic order and disorder. Pac. Symp. Biocomput. 2001;89-100.
65. Dyson H.J., Wright P.E. Coupling of folding and binding for unstructured proteins. Curr. Opin. Struct. Biol. 12:2002;54-60.
66. Uversky V.N. What does it mean to be natively unfolded? Eur. J. Biochem. 269:2002;2-12.
67. Adzhubei A.A., Sternberg M.J. Left-handed polyproline II helices commonly occur in globular proteins. J. Mol. Biol. 229:1993;472-493.
68. Adzhubei A.A., Laughton C.A., Neidle S. An approach to protein homology modelling based on an ensemble of NMR structures: application to the Sox-5 HMG-box protein. Protein Eng. 8:1995;615-625.
69. Williamson M.P. The structure and function of proline-rich regions in proteins. Biochem. J. 297:1994;249-260.
70. Kay B.K., Williamson M.P., Sudol M. The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J. 14:2000;231-241.
71. Mayer B.J. SH3 domains: complexity in moderation. J. Cell Sci. 114:2001;1253-1263.
72. May P., May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene. 18:1999;7621-7636.
73. Ko L.J., Prives C. p53: puzzle and paradigm. Genes Dev. 10:1996;1054-1072.
74. Pontius B.W. Close encounters: why unstructured, polymeric domains can increase rates of specific macromolecular association. Trends Biochem. Sci. 18:1993;181-186.
75. Dunker A.K., Obradovic Z. The protein trinity - linking function and disorder. Nature Biotechnol. 19:2001;805-806.
76. Wright P.E., Dyson H.J. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J. Mol. Biol. 293:1999;321-331.
77. Donaldson L., Capone J.P. Purification and characterization of the carboxyl-terminal transactivation domain of Vmw65 from herpes simplex virus type 1. J. Biol. Chem. 267:1992;1411-1414.
78. Dahlman-Wright K., Baumann H., McEwan I.J., Almlof T., Wright A.P., Gustafsson J.A., Hard T. Structural characterization of a minimal functional transactivation domain from the human glucocorticoid receptor. Proc. Natl Acad. Sci. USA. 92:1995;1699-1703.
79. Kriwacki R.W., Hengst L., Tennant L., Reed S.I., Wright P.E. Structural studies of p21Waf1/Cip1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity. Proc. Natl Acad. Sci. USA. 93:1996;11504-11509.
80. Triezenberg S.J. Structure and function of transcriptional activation domains. Curr. Opin. Genet. Dev. 5:1995;190-196.
81. Brinkmann U., Mattes R.E., Buckel P. High-level expression of recombinant genes in Escherichia coli is dependent on the availability of the dnaY gene product. Gene. 85:1989;109-114.
82. Gill S.C., von Hippel P.H. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 1989;182.
83. Nichols N.M., Matthews K.S. Human p53 phosphorylation mimic, S392E, increases nonspecific DNA affinity and thermal stability. Biochemistry. 41:2002;170-178.
84. Jaenicke R., Rudolf R. Refolding and association of oligomeric proteins. Methods Enzymol. 131:1986;218-250.
85. Stoll R., Renner C., Hansen S., Palme S., Klein C., Belling A., et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry. 40:2001;336-344.
86. Schmid F.X. Protein Structure: A Practical Approach. 1997;IRL Press, Oxford, UK.
87. Piotto M., Saudek V., Sklenar V. Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions. J. Biomol. NMR. 2:1992;661-665.
88. Uversky V.N., Gillespie J.R., Fink A.L. Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins: Struct. Funct. Genet. 41:2000;415-427.
89. Cuff J.A., Clamp M.E., Siddiqui A.S., Finlay M., Barton G.J. JPred: a consensus secondary structure prediction server. Bioinformatics. 14:1998;892-893.